Loading clinical trials...

RECRUITING

PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.

Prospective PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.

NCT06247163•University Hospital, Essen

Summary

There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF

Detailed Description

The main objective of this study is to determine whether patients with SCLC who have a metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor rest by PET CT and biopsy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histopathologic confirmation
•Limited disease

Exclusion Criteria

•Other histology than small cell lung cancer
•Further tumor diagnosis
•ECOG 3 or worse
•Extensive disease
•stage IV

Locations (1)

University Hospital Essen

Essen, Germany

Key Dates

Start Date

February 22, 2024

Primary Completion Date

June 22, 2025

Completion Date

June 22, 2029

Last Updated

September 27, 2024

Enrollment

ESTIMATED participants

Conditions

Small Cell Lung Carcinoma

Interventions

PET based Raditherapy boost

RADIATION

Contacts

Maja Guberina

CONTACT

020172383121 maja.guberina@uk-essen.de

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Advanced Solid TumorAdvanced Malignant Neoplasm+28 more

View study

RECRUITINGPHASE1

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923

Carcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 27, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.

Inclusion Criteria

Exclusion Criteria

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A Study of LY4175408 in Participants With Advanced Cancer

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer